The Effect of Medical therapy on Metabolic Syndrome in Women with Polycystic Ovary Syndrome

سال انتشار: 1397
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 394

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

LAMOGMED03_038

تاریخ نمایه سازی: 21 بهمن 1397

چکیده مقاله:

Introduction: Polycystic ovary syndrome (PCOs) is associated with cardiovascular risk factors such as metabolic syndrome, diabetes, endothelial dysfunction, and subclinical atherosclerosis. The first line treatment for people with PCOs is the administration of contraceptive pills. But There is broad discussion about the effects of contraceptive pills on metabolic syndrome indices. The purpose of these studies was to compare the effect of Cyproterone compound and Yasmin® on the metabolic syndrome indices in women with PCOs.Methods: A clinical trial was conducted on 39 women 18-28 years old with a diagnosis of metabolic syndrome and PCOs. Women with complaints oligomenorrhea associated with clinical manifestations of hirsutism or acne was assessed for clinical features of PCOS, hormonal and biochemical parameters. PCOS was defined as diagnostic criteria of 2003 census Rotterdam. The National Cholesterol Education Program (NCEP) - Adult Treatment Panel (ATP III) Criteria was used to determine having metabolic syndrome. The eligible women were randomly allocated to two groups. One group was received one tablet Yasmin® (30 μg ethinylestradiol and 3 mg drospirenone) daily while, another group was received one tablet Cyproterone compound (containing 35 μg ethinylestradiol and 2 mg cyproterone acetate) daily for 4 months. Body weight, height, waist circumference, and blood pressure were determined at baseline and the end of the treatment. Fasting blood samples for LDL-cholesterol, HDL-cholesterol, total cholesterol, triglyceride, and FBS was taken at baseline and the end of the treatment. Improvement in indices of metabolic syndrome was as primary outcome after 4 months of medication. Secondary outcome was spontaneous menses within 6 months after drug discontinuation.Results: After 4 months of treatment, the metabolic syndrome was decreased in 63.2% vs. 65% in Yasmin® group and Cyproterone compound group. The Yasmin® group showed a significant reduction in HDL-cholesterol (P=0.029), total cholesterol (p=0.004), body weight (p = 0.001), and abdominal circumference (p=0.002). HDL-cholesterol (p<0.0001) and body weight (p=0.030) was also significantly decreased by Cyproterone compound. Spontaneous menses was reported in 78.9% vs. 95% in Yasmin® group vs. Cyproterone compound group, at 6 months stopping treatment.Conclusion: The study showed that the the number needed to treat (NNT) in the Yasmin® group compared to the Cyproterone compound was 55. Therefore, the difference between the two groups was worthless, and showed similar effects.

نویسندگان

Mouloud Agajani Delavar

Infertility and Reproductive Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

Sedigheh Esmailzadeh

Infertility and Reproductive Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran